International Biotechnology Trust (IBT) has delivered a solid performance of 14.3% in NAV terms this year and grown its dividend by 4.1% in the face of difficult conditions for biotech companies. Volatility in broader equity markets – spooked by fears of a trade war, the Brexit debacle, and tensions in the Middle East – has not helped biotech, which tends to perform poorly in ‘risk off’ environments, but IBT’s unquoted portfolio, a unique feature of the trust, has lent considerable support to NA ....
12 Dec 2019
International Biotechnology Trust - Overview
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
International Biotechnology Trust - Overview
International Biotechnology Trust PLC (IBT:LON) | 627 0 0.0% | Mkt Cap: 236.9m
- Published:
12 Dec 2019 -
Author:
William Heathcoat Amory -
Pages:
7
International Biotechnology Trust (IBT) has delivered a solid performance of 14.3% in NAV terms this year and grown its dividend by 4.1% in the face of difficult conditions for biotech companies. Volatility in broader equity markets – spooked by fears of a trade war, the Brexit debacle, and tensions in the Middle East – has not helped biotech, which tends to perform poorly in ‘risk off’ environments, but IBT’s unquoted portfolio, a unique feature of the trust, has lent considerable support to NA ....